Archives: Agenda

Navigating the future of clinical trial logistics

Insights from the DHL logistics trend radar

  • Key logistics trends impacting life sciences & healthcare
  • Customer insights on adoption and priorities: LTR ECHO
  • What’s next in the DHL logistics trend radar

CLOSING PANEL DISCUSSION: How AI is powering a new era of cancer drug discovery and development

  • Moving from basic functionalities to more meaningful impact and examples of this in practice
  • When AI is progressing so quickly, how will regulation evolve to match this speed?
  • When is AI not the answer?
  • How AI has revolutionised innovative ways of collecting data, biosimulation, and early disease diagnosis for oncology trials

Moderator: Asiyah Nawab, Senior Healthcare Analyst (Immunology Team), GlobalData

THIS SESSION WILL BE IN THE ONCOLOGY CONFERENCE ROOM

Clinical trials in rare immunology disorders

  • Overview of rare diseases in Immunology
  • Pharma focus on rare diseases in Immunology for drug development – where do industry interests lie?
  • Challenges in rare disease trials in immunology
  • Case Study – Sarepta’s Elevidys in Duchenne Muscular Dystrophy (DMD)

The role of patient research NGOs in drug development – illustrated by the Children’s Tumor Foundation’s leadership role in the EU PEARL project

  • Patient driven infrastructure – NF patient registry, NF Preclinical Hub, NF Clinic Network, NF Data Portal – to accelerate trials and insights
  • CTF served as IMI research partner on EU PEARL NF1; CTF Europe launched to expand platform trials
  • EU PEARL NF1: adaptive platform basket across PN, cNF, LGG/OPG; observational entry → randomization; add/drop arms, early go/ no go signals
  • Addresses EMA orphan challenges via clear estimands and central oversight; efficient, de risked paediatric evidence
  • NGO impact: contributed to first NF approvals; 60+ US trials; now scaling European execution